Objective: Diffuse large B cell lymphomas (DLBCL) are clinically and morphologically heterogen diseases. There are more than 150 gene mutations in DLBCL. Mutations effect disase survey by histon modification, cell proliferation, cell metabolism and differentiation, apoptosis, response to DNA injury, B cell and Toll-like receptor signalization, angiogenesis and immun regulation in patients with DLBCL. We aim to search gene expression frequency, the relation of mutative genes expression with treatment response and survey in patients with DLBCL.

Methodology: The DNAs of patients with DLBCL obtained from formalin fixed paraffin embedded biopsy material in Pathology Department as retrospectively. Illumina genom analyzer and qiaqen method for bioinformatic software was used. Total 141 gene were evaluated. SPSS 17.0 were used for statistically analyses. We used Shapiro-Wilk test relevance for distrubition. The results were described as a number, frequency, and percentage. The chi-squared and Student's T, Mann–Whitney U tests were used for the analysis. The results were assessed at a 95% confidence interval and a p-value of less than 0.05 was accepted as significant.

Results: We found mutation in 13 of 141 genes. The pathological genes were ANKRD26, BRCA1, BRCA2, EZH2, KMT2C, MSH6, MYC, MYD88, NF1, NOTCH1, PMS2, PTEN and WRN. There were relations among ANKRD26, BRCA2, MYD88, NOTCH1 genes with prognosis. The remission rates in patients with ANKRD26, BRCA2, MYD88, NOTCH1 were 33.3% (p<0.05), 52.4% (p<0.05), 0% (p<0.05), 37.5% (p>0.05), respectively. The relapse rates in patients with ANKRD26, BRCA2, MYD88, NOTCH1 gene mutation were 58.3% (p<0.05), 38.1% (p=0.37), 66.7% (p=0.23), 62.5% (p=0.03), respectively.

Conclusion: ANKRD26, BRCA2, MYD88, NOTCH1 genes effect prognosis in patients with DLBCL. Aggressive treatment can be useful in patients DLBCL that have ANKRD26, BRCA2, MYD88, NOTCH1 gene mutations.